Streetbeat News

Regulatory

BCLI

BrainStorm Cell Therapeutics is set to meet with the US FDA to discuss the development plan for NurOwn, a treatment for ALS. The company is withdrawing its Biologics License Application (BLA) for NurOwn, a decision coordinated with and viewed by the FDA as a withdrawal without prejudice. BrainStorm remains committed to the ALS community and is exploring next steps for NurOwn, including publishing emerging clinical data and developing a protocol for an additional clinical study.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 10:03 am

SPY

VGK

Russian President Vladimir Putin has criticized the US for supplying ATACMS to Kyiv, calling it a mistake. He also ordered Russian warplanes equipped with Kinzhal missiles to regularly patrol the Black Sea, according to reports from Reuters, Tass, and IFAX.

Portfolio Pulse from Charles Gross

October 18, 2023 | 9:58 am

SPY

Federal Reserve's Harker has called for an extension of the pause on interest-rate increases, suggesting to 'see how things evolve' over the next few months. This news was reported by the Wall Street Journal.

Portfolio Pulse from Charles Gross

October 18, 2023 | 9:39 am

EIS

SPY

USO

President Biden, in a meeting with Israeli Prime Minister Netanyahu, suggested that the recent conflict was initiated by 'the other team', not Israel, according to NBC News.

Portfolio Pulse from Charles Gross

October 18, 2023 | 9:36 am

IHI

Elon Musk's Neuralink could generate over $220M in revenue from its N1 brain implant for ALS patients by 2030, according to Ark Investment Management analyst Pierce Jamieson. The N1 implant and R1 surgical robot are awaiting FDA approval. The technology could transform medicine and accelerate the link between humans and artificial intelligence, Jamieson said. Neuralink recently received FDA approval to commence its first-in-human clinical trial.

Portfolio Pulse from Shanthi Rexaline

October 18, 2023 | 9:16 am

FXI

SPY

China's Foreign Ministry has lodged stern representations with the U.S. over the latest chip restrictions, stating that such restrictions and forced de-coupling for political purposes violate the principles of the market economy and fair competition.

Portfolio Pulse from Charles Gross

October 18, 2023 | 9:16 am

VGK

The Eurozone's September Consumer Price Index (CPI) and Core CPI both met estimates, with a month-on-month increase of 0.3% and 0.2% respectively.

Portfolio Pulse from Charles Gross

October 18, 2023 | 9:03 am

VGK

The Eurozone Consumer Price Index (CPI) for September was reported at 4.3%, matching the estimated figure but lower than the prior figure of 5.2%.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 9:02 am

VGK

The Eurozone Consumer Price Index (CPI) for September was reported at 0.3%, in line with estimates but lower than the 0.5% reported in the previous month.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 9:02 am

VGK

The Eurozone Core Consumer Price Index (YoY) for September was reported at 4.5%, in line with estimates but lower than the previous figure of 5.3%.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 9:01 am